Zoetis stock: recent performance and context

Zoetis (ZTS) has drawn attention after a steep share price decline, with the stock down about 31% over the past month and about 38% over the past 3 months, which has shifted investor focus toward fundamentals.

At a share price of US$80.23, Zoetis has seen its short term momentum weaken, with a 30 day share price return down 31%, and a 1 year total shareholder return down 51%, pointing to fading sentiment despite underlying profitability.

If recent volatility has you rethinking where you look for opportunities, this can be a useful moment to broaden your search and check out 20 top founder-led companies

With Zoetis stock down sharply despite ongoing profitability and growth in both revenue and net income, the key question now is simple: is this sell-off creating a potential undervaluation, or is the market already pricing in the company’s future growth?

Most Popular Narrative: 13.7% Undervalued

Zoetis last closed at $80.23, while the most followed narrative on the stock pegs fair value at $92.92, suggesting a noticeable valuation gap to interrogate.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword. The company cites generics as a potential risk in its financial statements. I’m not sure how much of this could be attributable to the 11% YoY decline in Pet segment revenues, but this is just something to watch out for if you’re interested in investing in the business.

Want to see why a business with mid single digit revenue growth, steady margins and debt funded buybacks still screens as undervalued here? The full narrative walks through how earnings power, capital allocation choices and a relatively low implied earnings multiple come together to justify that fair value estimate.

Result: Fair Value of $92.92 (UNDERVALUED)

However, this depends on US Companion Animal weakness and growing generic competition not worsening further. Both of these factors could quickly challenge that 13x P/E undervaluation story.

Next Steps

If this mix of concerns and optimism feels familiar, it can be a good time to review the data directly and act promptly to form your own stance using 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If Zoetis has sharpened your focus on fundamentals and valuation, do not stop here. Broaden your watchlist with a few focused idea lists built from data.

• Target steady compounding potential by scanning companies that look attractively priced on quality and value filters through the 46 high quality undervalued stocks
• Prioritize defense and sleep well at night by reviewing 65 resilient stocks with low risk scores that score well on resilience and downside protection.
• Get ahead of the crowd by hunting for underfollowed opportunities using the screener containing 22 high quality undiscovered gems before they show up on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.